Abstract
In the face of the COVID-19 pandemic, understanding the interplay between environmental factors and virus spread is crucial for global preparedness strategies. This study explores how geographic latitude, sunshine duration, and vitamin D status were associated with the incidence and fatality rates of COVID-19 across 187 countries during the crucial early months of the outbreak. Data on the total number of COVID-19 cases by country were obtained from the United Nations database as of June 30, 2020. Univariate and multivariate regression analyses were conducted to determine the associations between COVID-19 cases and latitude, average hours of sunshine from January to June, and mean 25-hydroxyvitamin D (25(OH)D) levels. The average COVID-19 prevalence and mortality per million population were 2,087 and 69, respectively, with a case fatality rate of 3.19%. COVID-19 case fatality rate was positively associated with latitude (β = 0.030; 95% CI: 0.008, 0.052) and negatively associated with hours of sunshine (β = -1.51; 95% CI: -4.44, 1.41) and 25(OH)D levels (β = - 0.054; 95% CI: -0.089, -0.019) in adjusted regression analyses. Findings were similar for COVID-19 prevalence and mortality rate. These findings indicate that higher latitude and lower 25(OH)D levels was associated with increased COVID-19 severity and mortality.
While the data highlight potential links between vitamin D status and COVID-19 outcomes, causality cannot be inferred. Further research, including large-scale, well-controlled trials, is essential to determine whether vitamin D plays a definitive role in COVID-19 prevention and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I declare that I have no financial interests that could have influenced the work reported in this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study utilized publicly available, aggregated data at the country level from reputable sources such as the World Health Organization and the World Bank. No individual-level or personally identifiable information was collected or analyzed. Therefore, ethical approval and informed consent were not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.